For example, serious side effects were reported after treatment with CAR T cells targeting CD19 or other antigens due to nervous system disorders, cytokine release syndrome or other CAR T cell-associated side effects, such as on-target/off-tumor toxicity against healthy tissues expressing the targeted tumor-associated antigens (TAAs) (16–18). The gene discussed is CD19; the disease is neoplasm.